McKesson Extends Pharmaceutical Distribution Agreement with CVS Health
Key Facts
McKesson announced an extension of its existing pharmaceutical distribution agreement with CVS Health. According to investing.com, McKesson shares rose following the announcement of the partnership extension, which secures a key revenue stream and ensures continuity in the supply chain relationship between the major US drug distributor and the pharmacy chain.
MCK closed at $853.81 on September 30, 2026, having reached a day high of $866.19 and a low of $847.3 during that session. The renewal of this large-scale contract provides significant visibility and stability for the company's operations within the healthcare sector.
Latest Updates · 1
- Notable·
Update: The agreement between McKesson and CVS Health has been officially extended through June 2032. Following the extension, McKesson reaffirmed its adjusted EPS guidance for fiscal year 2027, signaling confidence in the long-term cash flow stability derived from the partnership.